definiens: with respect to a Product shall mean any product, other than a Product soldby or for [COMPANY] or its Affiliates or its or their sublicensees ( but, for the avoidance of doubt, including a Product if sold by aThird Party not sublicensed for such Product by [COMPANY] ), that is sold under a marketing authorization granted by aRegulatory Authority to a Third Party for the same or an overlapping indication or indications as the relevant Product, wheresuch marketing approval was obtained based upon submission of an abbreviated regulatory data package rather thansubmission of the full preclinical and clinical safety and efficacy data that would be required for a new molecule by virtue ofits similarity to a Product ( excluding, for the avoidance of doubt, approval based upon a grant by [COMPANY] or its Affiliate orany Sublicensee of a right of reference to data related to any Product ), either ( 1 ) through a formalized regulatory process forapproval of or versions of biological pharmaceutical products in the applicable country, or ( 2 ) if nosuch formalized regulatory process for approval of or versions of biological pharmaceutical productsexists in such country, because such product contains as an active pharmaceutical ingredient a CTLA-4 variant molecule thathas the same amino acid sequence as the Compound that is the active pharmaceutical ingredient in the applicable Product ( orsuch CTLA-4 variant is so substantially similar to the Compound that it is treated as the same molecule, for regulatorypurposes, as the applicable Compound in the relevant Product ) . Notwithstanding the foregoing, the following shall not beconsidered Generic Products for purposes of this Section 2.1.3(b ): ( X ) belatacept or abatacept ( and any products containingeither or both ), ( Y ) any product containing as an active pharmaceutical ingredient a molecule that has the same amino acidsequence as abatacept or belatacept, and ( Z ) any product that is approved on the basis of being a or version of abatacept or belatacept ( i.e., is approved on the basis of similarity of its active pharmaceutical ingredient to eitherabatacept or belatacept in the manner described above with respect to Generic Products approved on the basis of similarity tothe relevant Compound )